MedTrace Logo

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

NCT01096511 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1001

Last updated 2013-06-21

No results posted yet for this study

Summary

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.

Conditions

  • Secondary Peritonitis
  • Abscess, Intra-Abdominal

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01096511 on ClinicalTrials.gov